Call us:  949-768-2988

GeneSight Pharmacogenomic Testing

  • Depression, anxiety, bipolar disorder, schizophrenia or other behavioral health conditions.
  • Narrows down medications without having to test them out.

  • Affordable with payment options on a sliding scale.
  • Only requires a simple cheek swab that takes less than 5 minutes.
  • Call for more information

Finding the right depression or anxiety medicine for you just got easier

Sample Patient Report

Advanced TMS Center              

Specializing in depression treatment with Medications and TMS

A sample genesight report summary. 

Advanced TMS Center founder Dr. Kinback discussing the benefits of Genesight.

About the Test

GeneSight by Assurex Health is a laboratory developed pharmacogenomic test that uses cutting edge technology to measure and analyze clinically important genomic variants in the treatment of psychiatric disorders. The results of the GeneSight report can help a clinician understand the way a patient’s unique genomic makeup may affect certain psychiatric medications. The analysis is based on pharmacogenomics, the study of genomic factors that influence an individual’s response to medication treatments, manufacturers’ FDA-approved drug labels, peer-reviewed scientific and clinical publications, and proven drug pharmacology. Quick turnaround time, combined with an individualized report of the patient’s genomic makeup, clinical experience, and other factors can provide information to help a physician make personalized medication treatment choices for each patient. In clinical use for more than 5 years, GeneSight has over 13,000 registered healthcare providers and over 230,000 patients have undergone GeneSight testing.

Multiple clinical studies show that when doctors use GeneSight to guide their treatment, patients are twice as likely to get on the right medication. Plus, with treatment guided by GeneSight, patients saw a 70% greater improvement in their symptoms versus usual treatment.*
*Source: Hall-Flavin DK et. al, Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenetics and Genomics. 2013;23(10):535-548.